ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1194

A Module on Large Vessel Vasculitis for Learners in Rheumatology
Abstract Number: 1255

A Molecular Signature Response Classifier Predicts the Likelihood of Non-response to TNF Inhibitor Therapies in RA at 3 Months
Abstract Number: 0325

A Multianalyte Assay Panel with Cell-bound Complement Activation Products Demonstrates Clinical Utility for the Diagnosis and Treatment of Systemic Lupus Erythematosus
Abstract Number: 0729

A Multicenter, Observational, Extension Study Evaluating the Safety, Tolerability, and Efficacy of a Single Lorecivivint Injection in Knee OA Subjects
Abstract Number: 1560

A Multidisciplinary Timely Approach to Initiate Immunosuppressive Biologic Therapy and Improve COVID-19 Cytokine Storm Syndrome Outcome
Abstract Number: 1079

A Multifaceted Approach to Increasing Enrollment and Activation of Pediatric Rheumatology Patient Portal Profiles
Abstract Number: 1223

A Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease-Modifying Therapies: 6-Month Effectiveness and Patient Reported Outcome Data from the European Cohort
Abstract Number: 0570

A Narrowed, but Persistent Mortality Gap: A National, Matched Cohort Study in U.S. Veterans with Rheumatoid Arthritis from 2000-2017
Abstract Number: 0487

A Needs Assessment for the Transition into a Rheumatology Program Director Role: Survey of Current and Former Rheumatology Program Directors
Abstract Number: 1936

A Neutrophil Degranulation Signature Identifies Proliferative Lupus Nephritis
Abstract Number: 0031

A New Pharmacostatistical Model to Assess MTX-adherence in RA Patients
Abstract Number: 1185

A New Virtual Reality: Needs Assessment and Gains in Current Trainees Experience with a Novel Video-Based Post Rheumatology Rotation Intervention
Abstract Number: 0733

A New Wearable Transcutaneous Electrical Nerve Stimulation Device (actiTENS®) Is More Efficient and Better Tolerated Than Weak Opioids in the Treatment of Knee Osteoarthritis Pain
Abstract Number: 0845

A Non-Interventional Prospective Observational Study of Treatment with Etanercept Biosimilar (SB4) in Rheumatoid Arthritis in Real Life Clinical Practice; Interim Analysis of the ‘BENEFICIAL’ Study
Abstract Number: 0012

A Novel Mechanism Linking Mucosal Bacteria with Autoantibody Responses in RA: Acetylated Bacterial Lysate as a Model Antigen

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].